The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. But this progress casts a puzzling shadow.
The drugs come at a high cost for relatively limited benefits, offering only a brief respite in the pace of cognitive decline. This reality raises a question: Are we fixated on such marginally effective treatments at the expense of more promising preventive measures?
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
recent posts
Mark Sisson separates longevity fads from the habits that consistently improve health and performance
Flawed scientific thinking lies at the heart of postmodern scientific, medical, and institutional failures
Dr. Drew traces the roots of modern misinformation to scientific illiteracy and a growing intolerance for uncertainty, debate, and dissent.
